Intradermal reaction testing is an essential biocompatibility evaluation used to assess whether single-use medical consumables release irritating substances that could cause local tissue reactions in patients. Performed in accordance with ISO 10993-10 and GB/T 16886.10, this test is a mandatory component of biological safety documentation for regulatory submissions such as NMPA registration, FDA clearance, and EU MDR conformity assessment. This article explains the technical principles, sample preparation requirements, testing procedures, scoring criteria, and typical applications of intradermal reaction testing for disposable medical devices.
Technical Overview
The intradermal reaction test, also referred to as the intracutaneous reactivity or irritation test, is a laboratory assay designed to evaluate the local irritation potential of extractable substances released from medical devices and materials. For single-use medical consumables—products intended for one-time use on a single patient, such as syringes, infusion sets, catheters, and wound dressings—this test plays a critical role in confirming biological safety before market release.
Because disposable consumables come into direct contact with intact skin, mucous membranes, breached skin, or internal tissues, any residual monomers, plasticizers, processing aids, mold release agents, or sterilant residues that migrate out of the material may provoke inflammatory responses such as erythema (redness) and edema (swelling). The intradermal reaction test detects these hazards by preparing polar and non-polar extracts of the finished product and injecting them into the skin of rabbits, after which the injection sites are observed and scored over a 72-hour period.
The test is specified in ISO 10993-10 (Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization) and its Chinese counterpart GB/T 16886.10, while sample preparation follows ISO 10993-12. It is generally required for devices categorized under ISO 10993-1 as surface-contacting devices (breached or compromised skin, mucosal membranes) and external communicating devices, making it one of the most frequently performed biocompatibility tests for disposable medical consumables.
Testing Samples
Sample Selection Principles
Test samples should be representative of the finished product in its final manufactured, cleaned, and sterilized condition whenever possible. If the complete device cannot be extracted as a whole, representative portions of the materials that contact the patient should be selected, ensuring that all materials, additives, and surface treatments present in the final product are represented in the extraction.
- Final products sterilized by the intended clinical method are preferred, since sterilization (e.g., ethylene oxide, gamma irradiation) can generate new extractable by-products.
- When testing components separately, the ratio of each material in the test sample should reflect its proportion in the actual device.
- Samples should be cut, handled, and extracted under controlled, contamination-free conditions to avoid false positive results.
Extraction Media
Two extraction media with contrasting polarity are used to capture both hydrophilic and lipophilic extractables, as required by ISO 10993-12:
- Polar medium: sodium chloride injection (0.9% saline) or culture medium, suitable for extracting water-soluble substances.
- Non-polar medium: pharmacopoeial-grade vegetable oil such as sesame or cottonseed oil, suitable for extracting lipid-soluble substances.
Extraction Ratios and Conditions
The ratio of sample surface area (or mass) to extraction medium volume is standardized to ensure reproducible and exaggerated extraction relative to clinical exposure:
- Solid materials with regular surfaces: 6 cm²/mL for thickness below 0.5 mm, 3 cm²/mL for thickness of 0.5–1.0 mm, and 1.25 cm²/mL for thickness above 1.0 mm.
- Irregularly shaped devices and polymeric or textile materials: typically 0.2 g of sample per mL of medium.
- Absorbent materials and hydrocolloids: typically 0.1 g per mL of medium.
- Common extraction conditions: 37 ± 1 °C for 24 ± 2 hours (most frequently applied), or alternatively 50 ± 2 °C for 72 ± 2 hours, 70 ± 2 °C for 24 ± 2 hours, or 121 ± 2 °C for 1 ± 0.2 hours, selected so that the material properties are not degraded.
Blank controls containing the same media subjected to identical extraction conditions without the test sample are prepared in parallel for comparison.
Testing Items
The core testing items evaluated in the intradermal reaction test include:
- Erythema and eschar formation: graded on a 0–4 scale from no reaction (0) through slight, well-defined, and moderate erythema to severe erythema with eschar formation (4).
- Edema: graded on a 0–4 scale from no swelling (0) to severe swelling extending beyond the raised area (4).
- Aggregate irritation score: the total of erythema and edema scores recorded at each observation point for all injection sites.
- Comparison index: the difference between the mean score of the test extract sites and the corresponding blank control sites, which determines pass or fail.
The test is designed to detect primary irritancy caused by direct chemical stimulation of tissue, rather than immune-mediated sensitization, which is evaluated by separate assays such as the guinea pig maximization test or murine local lymph node assay.
Testing Methods
Test System and Administration
Healthy adult albino rabbits (commonly New Zealand White rabbits) are used as the animal model, with a minimum of three animals per test. The fur on the dorsal area is clipped approximately 4 to 24 hours before injection, and animals with pre-existing skin lesions are excluded. Under the standard ISO 10993-10 protocol, each rabbit receives a series of 0.2 mL intradermal injections on both sides of the spine, typically arranged as follows:
- Five sites injected with the polar test extract and five sites with the polar blank control.
- Five sites injected with the non-polar test extract and five sites with the non-polar blank control.
Observation and Scoring
The injection sites are examined and scored for erythema and edema at 24, 48, and 72 hours after administration. Each site receives a combined erythema and eschar score and an edema score according to the standardized grading scales defined in ISO 10993-10. Any other observable reactions, such as necrosis, blistering, or depigmentation, are also documented.
Result Evaluation
For each rabbit, the scores from all sites and all observation time points are summed and averaged separately for the test extract and the blank control. The intradermal reactivity of the sample is expressed as the difference between these two mean values. If the difference between the test and control does not exceed 1.0 for both the polar and non-polar extracts, the sample is considered to meet the requirements and is regarded as non-irritant under the test conditions. All procedures are conducted under Good Laboratory Practice (GLP) principles and with institutional animal care and use approval.
Applications
Intradermal reaction testing supports biological safety evaluation across a broad range of disposable medical consumables and regulatory scenarios:
- Product registration and market approval: biocompatibility documentation for NMPA registration in China, FDA 510(k) and PMA submissions in the United States, and technical files under the EU Medical Device Regulation (MDR).
- Typical product categories: hypodermic syringes and needles, infusion and transfusion sets, indwelling catheters, urinary catheters, endotracheal tubes, medical gloves, wound dressings, gauze and adhesive bandages, blood collection systems, dialysis consumables, oxygen masks, and anesthesia breathing circuits.
- Change control and requalification: assessment of new raw materials, changes to suppliers, manufacturing processes, or sterilization methods that may alter the extractable profile of the consumable.
- Risk management support: providing toxicological evidence as part of the ISO 10993-1 biological evaluation plan and the overall risk management file under ISO 14971.
- Research and development: screening candidate materials and formulations early in the design cycle to avoid costly late-stage failures.
FAQ
Which standards govern intradermal reaction testing?
The test method is specified in ISO 10993-10 and GB/T 16886.10, while sample selection, extraction media, ratios, and conditions are defined in ISO 10993-12. The overall testing strategy is determined by the contact categorization framework of ISO 10993-1.
How many animals are required?
A minimum of three healthy rabbits is required under the standard protocol. If results are equivocal or inconsistent between animals, additional animals may be added according to the standard's provisions.
How long does the test take?
Extraction typically requires 24 to 72 hours depending on the chosen condition, followed by a 72-hour in vivo observation period. Including animal acclimation and report preparation, the complete study generally takes two to four weeks.
Why are both polar and non-polar extracts tested?
Body tissues encounter both aqueous and lipid environments. Using a polar medium such as saline and a non-polar medium such as vegetable oil ensures that both hydrophilic and lipophilic irritants that could leach from the consumable are detected, providing comprehensive coverage of the extractable profile.
What does a positive (failing) result indicate?
A positive result suggests the presence of irritating leachables, which may originate from raw materials, additives, molding or assembly aids, sterilant residues, or packaging interactions. Manufacturers should investigate the cause through chemical characterization per ISO 10993-18, consider material substitution or improved post-processing, and retest after corrective action.
Are in vitro alternatives available?
Reconstructed human epidermis-based in vitro irritation methods are increasingly accepted by some regulators for certain device categories and can reduce animal use in line with the 3Rs principle. However, for many single-use consumable submissions, the rabbit intradermal test remains the widely recognized reference method, and the choice of approach should be justified within the biological evaluation plan.